


## SZL P1-41

<b>Cat. No.:</b>	HY-100237		
<b>CAS No.:</b>	222716-34-9		
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>24</sub> N <sub>2</sub> O <sub>3</sub> S		
<b>Molecular Weight:</b>	420.52		
<b>Target:</b>	E1/E2/E3 Enzyme; Apoptosis		
<b>Pathway:</b>	Metabolic Enzyme/Protease; Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 2.5 mg/mL (5.95 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.3780 mL	11.8900 mL	23.7801 mL
5 mM	0.4756 mL	2.3780 mL	4.7560 mL
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

SZL P1-41 is a specific Skp2 inhibitor, binds to the F-box domain of Skp2 to prevent Skp1 association and Skp2 SCF complex formation. SZL P1-41, like Skp2 deficiency, augments p27-mediated apoptosis/senescence, while it impairs Akt-driven glycolysis. Anti-tumor activities<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

Skp2<sup>[1]</sup>

#### In Vitro

SZL P1-41 (5-20μM; 24 hours) induces endogenous p27 protein expression in PC3 cells and also induced expression of p21, another Skp2 substrate<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

SZL P1-41 (40-80 mg/kg; i.p.) displays a potent effect on inhibiting prostate and lung tumor growth in Nude mice bearing A549 and PC3 tumor xenografts<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- Leukemia. 2020 May;34(5):1241-1252.
- Cancer Sci. 2021 Jun 3.
- Life Sci. 2021 Dec 16;289:120231.
- In Vitro Cell Dev Biol Anim. 2021 Aug 5.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

- [1]. Chan CH et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013 Aug 1;154(3):556-68.
- [2]. Chan CH, et al. Skp2: a dream target in the coming age of cancer therapy. Cell Cycle. 2014;13(5):679-80.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA